Clinical Trial News
Waters Acquires Halo Labs to Enhance Biologic Therapy Analysis Capabilities
• Waters Corporation has acquired Halo Labs, gaining specialized imaging technology that detects particles in cell, protein, and gene therapies with capabilities beyond standard methods.
• The Aura platform's subvisible particle technology provides critical insights for CAR T-cell therapies by detecting translucent process impurities that conventional methods miss.
• This strategic acquisition strengthens Waters' position in specialized analytical technologies for emerging biopharmaceuticals, particularly supporting quality control in advanced therapy development.
Telomir Pharmaceuticals Secures $3 Million Investment to Advance Novel Age-Reversal Drug for Rare Diseases
• Telomir Pharmaceuticals has secured $3 million in premium equity financing from its largest shareholder to advance Telomir-1, a first-in-class age-reversal molecule, toward an IND submission for rare disease indications by year-end.
• The company's lead candidate, Telomir-1, targets five fundamental biological drivers of aging and has shown promising preclinical results across multiple conditions including Progeria, Wilson's disease, and Type 2 diabetes.
• Telomir is also developing Telomir-Ag2, a novel stabilized Silver(II) compound with broad-spectrum antimicrobial activity against drug-resistant pathogens, addressing a global market projected to exceed $30 billion.
Breakthrough Clinical Trial Shows Vagus Nerve Stimulation Significantly Improves Spinal Cord Injury Recovery
• UT Dallas researchers demonstrated unprecedented recovery rates for spinal cord injuries using closed-loop vagus nerve stimulation (CLV) combined with individualized rehabilitation.
• The clinical trial showed significant improvements in arm and hand function among participants with chronic cervical spinal cord injuries, regardless of age or time since injury.
• Following these promising results, researchers are advancing to a pivotal Phase 3 trial with 70 participants across multiple U.S. institutions, potentially leading to FDA approval.
Related Clinical Trials:
Baylor Research Institute
Posted 2/15/2021
ReShape Lifesciences Announces Merger with Vyome and Asset Sale to Biorad Amid Q1 2025 Financial Results
• ReShape Lifesciences reported Q1 2025 financial results showing revenue of $1.1 million, a 42.7% decrease from the same period in 2024, primarily due to competition from GLP-1 pharmaceutical weight-loss alternatives.
• The company is progressing toward finalizing its merger with Vyome Therapeutics and asset sale to Biorad Medisys, with the S-4 recently declared effective and plans to set a record date in the near future.
• ReShape strengthened its intellectual property portfolio with multiple patent allowances for its Diabetes Neuromodulation system and intragastric balloon technology, extending protection through at least 2039.
Basil Systems Secures $11.5M to Revolutionize Life Sciences Decision-Making with AI
• Basil Systems has raised $11.5 million in funding led by Golden Ventures, with participation from Hearst Ventures and Argosy Capital, to expand its AI-powered product lifecycle intelligence platform.
• The company has built BasilLink, the largest indexed dataset in life sciences with over 600 million records, providing real-time insights for regulatory submissions, clinical planning, and post-market surveillance.
• Already utilized by four of the five largest global medical device companies and in trials with major pharmaceutical firms, Basil's platform aims to transform fragmented regulatory and clinical data into actionable intelligence.
Fresenius Kabi Launches Tyenne®, Canada's First Tocilizumab Biosimilar for Autoimmune Conditions
• Fresenius Kabi has commercially launched Tyenne®, the first and only tocilizumab biosimilar available in Canada, offered in both subcutaneous and intravenous formulations.
• Tyenne® is indicated for multiple inflammatory and immune conditions including rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis, cytokine release syndrome, and COVID-19 treatment.
• The biosimilar provides a cost-effective alternative to the reference biologic Actemra®, expanding access to treatment while being supported by KabiCare®, a comprehensive patient support program.
Meta-Analysis Confirms Efficacy of Traditional Chinese Medicine Si-Shen-Wan for Treating IBS-D
• A comprehensive meta-analysis of 34 randomized controlled trials involving 2,976 participants has validated the efficacy of Si-Shen-Wan (SSW) in treating diarrhea-predominant irritable bowel syndrome.
• The traditional Chinese medicine formula demonstrated significant improvements in multiple symptom scores including abdominal pain, diarrhea, abdominal distension, and loss of appetite in IBS-D patients.
• Researchers from leading Chinese medical institutions employed trial sequential analysis to ensure robust findings, potentially offering a valuable alternative treatment for this common functional gastrointestinal disorder.
Mazindol ER Shows Promising Dual Action Against Fentanyl Addiction in Preclinical Studies
• NLS Pharmaceutics' preclinical study demonstrates Mazindol ER significantly reduces both fentanyl's rewarding effects and withdrawal symptoms in rodent models, suggesting potential as a novel non-opioid treatment for opioid addiction.
• The drug's multi-receptor mechanism targets partial mu-opioid receptor agonism, 5-HT1A receptor activation, and orexin-2 receptor modulation, offering a unique approach compared to traditional addiction treatments.
• These findings will be presented at the 2025 ASCP Annual Meeting in Arizona, with researchers highlighting Mazindol's potential advantages over conventional ADHD medications that show limited efficacy for opioid dependence.
Protagenic Therapeutics Secures $3.1 Million to Advance CNS Drug Pipeline Following Phytanix Bio Merger
• Protagenic Therapeutics (Nasdaq: PTIX) has raised $3.1 million through warrant exchanges and exercises, bolstering its financial position to advance peptide-based drug candidates for CNS disorders.
• The funding comes immediately after Protagenic's business combination with Phytanix Bio on May 19, 2025, creating a unified company with six complementary drug programs targeting stress disorders, epilepsy, and obesity.
• The merged entity combines Protagenic's expertise in peptide therapeutics with Phytanix's specialization in cannabinoid and cannabinoid-like molecules, potentially strengthening their competitive position in neurological drug development.
BioDlink Secures Brazil GMP Certification, Expanding Global Reach for Bevacizumab Biosimilar
• BioDlink has successfully passed its first on-site GMP inspection by Brazil's ANVISA, a PIC/S member, marking a significant regulatory milestone for the company's Suzhou manufacturing facility.
• The inspection specifically reviewed production of Pusintin® (bevacizumab), a biosimilar antibody treating non-small cell lung cancer and metastatic colorectal cancer, receiving full approval with no observations.
• With regulatory certifications now in five countries including Brazil, Indonesia, Egypt, Colombia, and Argentina, BioDlink aims to expand access to affordable oncology biologics across emerging markets.